Posts

Recordati licenses Ionis drug

Recordati has licensed Ionis’s experimental RNA-based drug zilganersen (targeting Alexander disease) for exclusive ex-U.S. development and commercialization. Under the licensing agreement announced June 25, 2026, Ionis receives a $30 million upfront payment, additional milestone payments, and tiered royalties of up to the mid‐20% range on annual net sales. Ionis retains sole U.S. commercial rights and leads global development, while Recordati will manage regulatory filings and commercialization in all other countries. Vaxart’s BARDA funding cut refers to BARDA eliminating $100 million in funding earmarked for Vaxart’s norovirus vaccine program, effectively halting that specific BARDA-supported project. Sources: Ionis announces license agreement with Recordati for zilganersen ... Ionis licenses zilganersen to Recordati for ex-U.S. markets Recordati signs new Ionis licensing deal, shares trade steadily in ... Ionis, Recordati Ink $30M Zilganersen Deal - AllSci [PDF] PEO...

Merck KGaA buys Bio-Techne for $11.3 billion in largest deal in a decade

Friday Five: FDA steps up to counter China’s clinical‑trial edge, AbbVie buys Apogee, and psychedelics hype yields real data

BIO board met with national security, health officials on China’s biotech rise, CEO says (June 2026 news digestable summary)

Boehringer Ingelheim partners with Immunai on $15M AI‑driven T‑cell collaboration

FDA drops blood pressure device enforcement against Whoop

Gilead's Trodelvy Broad FDA Approval in Front-Line TNBC Fuels TROP2 ADC Market War

Ionis scores transformational FDA label expansion for Tryngolza

ADC Therapeutics cuts 17% of staff after 27 patient deaths in Zynlonta trial

Remix to take Nasdaq listing from Passage Bio in reverse merger for mRNA degrader platform

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering – June 24, 2026

Lilly offers up to $1.9B in new drug discovery deal with Abbisko

Ollin nets $330M to fund Phase 3 trials of Vabysmo challenger from China (OLN324)